Repository logo
 

Functional and molecular changes associated with intranasal buprenorphine in a healthy rodent model.

dc.contributor.advisorBaijnath, Sooraj.
dc.contributor.authorXhakaza, Sanelisiwe Penelope.
dc.date.accessioned2021-06-18T12:39:16Z
dc.date.available2021-06-18T12:39:16Z
dc.date.created2020
dc.date.issued2020
dc.descriptionMasters Degree. University of KwaZulu-Natal, Durban.en_US
dc.description.abstractOpioid addiction is a spiralling global epidemic associated with intense drug craving and the compulsive use of opiate drugs such as heroin, oxycodone, oxymorphone amongst others. Buprenorphine (BUP), commercially available as Subutex, is a partial opioid agonist that is used to treat opioid addiction and pain. It is associated with minimal risks of overdose and can be used outside of clinical care, making it the safest and most preferred choice of drug in the treatment of opioid addiction, over methadone and naltrexone. Literature suggests that opioids carry out their effects by altering the neurotransmitter systems of the brain viz. dopamine, norepinephrine, serotonin, glutamate and gamma-aminobutyric acid. Therefore, an ideal treatment drug should be able to counter these neurotransmitter changes in the brain. There is currently a lack of information on the pharmacodynamic effects of BUP in the brain, more specifically on how the drug affects brain neurotransmitter levels and its effect on the transcription factors Brain-derived neurotrophic factor (BDNF) and Cyclic AMP Response Element-Binding Protein (CREB). This study evaluates the pharmacokinetics of BUP, its effect on neurotransmitter levels and the expression of BDNF and CREB at various time points following a single dose. Sprague-Dawley rats received 36 μL of 0.3 mg/mL of BUP via intranasal administration. Following dosing, animals were euthanised and brain tissues were collected at different time points. A rapid and sensitive liquid chromatograph-mass spectrometry (LC-MS method was developed for the quantification of BUP and neurotransmitters (dopamine, serotonin, glutamate, norepinephrine and gamma-aminobutyric acid) in brain tissue and the expression of CREB and BDNF was determined using qPCR. This thesis is divided into three chapters. Chapter 1 contains a thorough background on BUP, opioid addiction and the role of neurotransmitters, BDNF and CREB. It also explains the principles of the quantification techniques used in this study i.e LC-MS and qPCR. Chapter 2 is a manuscript that was submitted to Addiction Biology titled “Functional and molecular changes associated with intranasal buprenorphine administration in a healthy rodent model”. Lastly, Chapter 3 provides a general conclusion and future recommendations for the study. The results in this present study indicate that BUP leads to significant changes in neurotransmitters, CREB and BDNF over time. Providing a better understanding of the mechanism of action of the drug, which could possibly improve the treatment of opioid addiction.en_US
dc.identifier.urihttps://researchspace.ukzn.ac.za/handle/10413/19495
dc.language.isoenen_US
dc.subject.otherDrug delivery.en_US
dc.subject.otherOpioid addiction.en_US
dc.subject.otherOpioids.en_US
dc.subject.otherDrug addiction.en_US
dc.subject.otherSubutex.en_US
dc.subject.otherDrug interactions.en_US
dc.subject.otherSprague-Dawley rats.en_US
dc.titleFunctional and molecular changes associated with intranasal buprenorphine in a healthy rodent model.en_US
dc.typeThesisen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Xhakaza_Sanelisiwe_Penelope_2020.pdf
Size:
1.68 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.64 KB
Format:
Item-specific license agreed upon to submission
Description: